ライフサイエンスコーパス: endothelin-1

1 creased production of vasoconstrictors (e.g. endothelin-1).

2 ure to vasoconstrictors (50 mM KCl and 20 nM Endothelin-1).

3 t in the eNOS/cGMP/PKG pathway and decreased endothelin-1.

4 on of vascular endothelial growth factor and endothelin-1.

5 ression of the proalgesic/algogenic mediator endothelin-1.

6 de (NO(.)) production and elevated levels of endothelin-1.

7 e including thymic stromal lymphopoietin and endothelin-1.

8 zed mesenteric arteries pre-constricted with endothelin-1.

9 cluding BNP (B-type natriuretic peptide) and endothelin-1.

10 (adjusted hazard ratio per log increment in endothelin-1, 1.57, 95% CI, 1.05-2.37; median follow-up,

11 on (adjusted odds ratio per log increment in endothelin-1, 1.66; 95% CI, 1.16-2.37).

12 (adjusted hazard ratio per log increment in endothelin-1, 1.69; 95% CI, 1.27-2.25; median follow-up,

13 ablished or to angiotensin II- (100 nmol/L), endothelin-1- (10 nmol/L), or phenylephrine- (10 micromo

14 ould be explained by an enhanced response to endothelin-1 (20% greater reduction in lumen diameter, P

15 her vehicle or IRL-1620 [Suc-[Glu9,Ala11,15]-Endothelin-1(8-12)] at 2, 4, and 6h post occlusion.

16 the effect of IRL-1620 [Suc-[Glu9,Ala11,15]-Endothelin-1(8-12)] on astrocytes, neurons, and vascular

17 Endothelin-1, a marker of endothelial dysfunction, is a

18 Endothelin-1, a potent vasoconstrictor, plays an importa

19 Endothelin-1, a very potent vasoconstrictor, is a key mo

20 We assessed the role of endothelin-1, acting through endothelin A (ET(A) ) recep

21 is determined by venous endothelium-derived endothelin-1, acting through its specific receptor Ednra

22 Angiotensin II and endothelin-1 activated Camui, largely through an oxidati

23 dicate for the first time that intracellular endothelin-1 activates endolysosomal ET(B) receptors and

24 these proteins in DN, and demonstrated that endothelin-1 activates podocytes to release heparanase.

25 Endothelin-1 activates the phospholipase C pathway, lead

26 Endothelin-1 acts in an intracrine fashion on endolysoso

27 uremic toxins (i.e., uric acid, phosphates, endothelin-1, advanced glycation end-products, and asymm

28 The endothelial specific mediator endothelin-1 along with interleukin (IL)-6, IL-8, tumor

29 Endothelin-1 also stimulates adrenal aldosterone synthes

30 eased expression of vasoconstrictor molecule endothelin 1 and a concomitant decrease in vasodilatory

31 We propose that downregulation of endothelin 1 and upregulation of vascular endothelial gr

32 ycoprotein to proteolipid protein 1 and both endothelin 1 and vascular endothelial growth factor.

33 of ARHGAP18 resulted in a failure to secrete endothelin-1 and a reduction in neutrophil transmigratio

34 r basal conditions and after the addition of endothelin-1 and abnormal spontaneous Ca(2+) release eve

35 (OPN) in mouse arteries via local release of endothelin-1 and activation of CREB.

36 y PGP levels associate with both circulating endothelin-1 and acute rejection in cardiac transplant p

37 nterleukin-6 and osteopontin, lowered plasma endothelin-1 and blood pressure, and improved mouse surv

38 eraction with GRK2 is inversely regulated by endothelin-1 and CAV1 scaffolding domain after liver inj

39 lacylcarnitines correlated with increases in endothelin-1 and creatinine/cystatin C, respectively.

40 be associated with higher levels of hepatic endothelin-1 and endocannabinoids, expression levels of

41 Epithelial-derived endothelin-1 and fibroblast growth factor were also augm

42 -beta1 signaling and increased expression of endothelin-1 and genes involved in VSMC contraction, hig

43 However, endothelin-1 and IL-6 increased, and IL-10 decreased, be

44 d increased contractility in the presence of endothelin-1 and larger basal mechanical tone in a uniqu

45 Levels of endothelin-1 and markers of fibrinolysis and inflammatio

46 ibited lower oxidative stress, expression of endothelin-1 and monocyte chemoattractant protein-1, and

47 Plasma endothelin-1 and OPN concentrations are positively corre

48 Despite pathophysiological links between endothelin-1 and pulmonary vascular remodeling, to our k

49 The levels of ET-1(endothelin-1) and Ang II (Angiotensin II) in the plasma

50 levels of the vasoconstrictor peptide ET-1 (endothelin-1) and higher levels of the 2 potent vasodila

51 ious pruritogens (histamine, chloroquine, or endothelin-1) and recorded spontaneous scratching before

52 ddressing 1 abnormality (eg, upregulation of endothelin-1) and were not developed specifically for PA

53 nce the hepatic vasoconstrictive response to endothelin-1, and aggravate hepatic microcirculatory dys

54 activation, such as smooth muscle actin and Endothelin-1, and all of these genes play a key role in

55 on, an enhanced vasoconstrictive response to endothelin-1, and an increased IHR were found to be asso

56 Circulating natriuretic peptides, endothelin-1, and catecholamine levels were unchanged.

57 (ICAM-1), anti-LG3, aminopeptidase N, CXCL9, endothelin-1, and gelsolin.

58 ated cytokines thymic stromal lymphopoietin, endothelin-1, and inflammatory tumor necrosis factor-alp

59 transforming growth factor beta1 (TGFbeta1), endothelin-1, and NAD(P)H oxidase 4 also occur in parall

60 In vitro, endothelin-1- and, in vivo, pressure overload-induced ca

61 artiles); no pulmonary hypertension and high endothelin-1; and no pulmonary hypertension and low endo

62 k involving transforming growth factor-beta, endothelin-1, angiotensin II, CCN2 (connective tissue gr

63 Phosphodiesterase-5 (PDE-5) inhibitors and endothelin-1 antagonists influence endothelial function

64 th simvastatin added to PDE-5 inhibitors and endothelin-1 antagonists showed transient improvement in

65 ate that BMP9 can affect the balance between endothelin-1, apelin, and adrenomedullin.

66 e previously showed that both heparanase and endothelin-1 are essential for the development of DN.

67 scription by Dot1a and HDAC2, and reinforces endothelin 1 as a therapeutic target of kidney fibrosis.

68 lly polarized molecular landscape identified endothelin 1 as an important secreted regulator of human

69 signaling in endothelial cells and identify endothelin-1 as an upstream input and Ras/MEK/ERK as a d

70 es of evidence have demonstrated the role of endothelin-1 as both a constrictor of uterine myometrial

71 tor-2, and the potent vasoconstrictive agent endothelin-1 as compared with control cells.

72 duced by AngII, and identify vasopressin and endothelin-1 as potential therapeutic targets to counter

73 In injured SECs, endothelin-1 blocked CAV1 phosphorylation induced by CAV

74 y in systemic sclerosis after macitentan, an endothelin-1 blocker.

75 emokine Receptor 2 (CXCR2) and production of endothelin-1 both in vitro and in vivo.

76 ls of the endothelium-derived C-terminal-pro-endothelin-1 (both p < 0.02).

77 a) and the neuroendocrine regulatory peptide endothelin-1 by DH82 cells.

78 fumigatus specifically caused production of endothelin-1 by epithelial cells in vitro but not any of

79 factors, TGF-beta1, TGF-beta2, periostin and endothelin-1, by human airway epithelial cells and in mi

80 Also, whether endothelin-1 can predict future heart failure and mortal

81 lymphopoietin-induced Ca(2+)-influx, whereas endothelin-1 caused itch-selective B-type natriuretic pe

82 tic peptide), and cGMP, and decreased plasma endothelin-1 compared with PH alone.

83 TGFbeta1 signaling via type I receptors and endothelin-1 contribute to mesenchymal lineage transitio

84 o-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1), and copeptin, in 3717 patient

85 procalcitonin, MR-pro-adrenomedullin, CT-pro-endothelin-1, CT-pro-arginine vasopressin, and MR-pro-at

86 endothelial nitric oxide synthase (eNOS) and endothelin-1; (d) immunohistochemistry of eNOS, endothel

87 Plasma endothelin-1 decreased during heating in controls but no

88 Endothelin-1 differentially directs lineage specificatio

89 nd GNAI3 are core signaling molecules of the endothelin-1-distal-less homeobox 5 and 6 (EDN1-DLX5/DLX

90 ane and accumulate in the nucleus, while the endothelin-1 does not cause nuclear GRK5 localization.

91 This evidence suggests that endothelin-1 drives development of glomerulosclerosis an

92 ist, we demonstrated for the first time that endothelin-1 drives many features of airway remodelling

93 eir interactions with other signals, such as Endothelin 1 (Edn1) and Jagged/Notch, which pattern the

94 previous studies have shown roles for BMPs, Endothelin 1 (Edn1) and Jagged1b-Notch2 in DV patterning

95 orsal Jag1 expression but also by inhibiting endothelin 1 (Edn1) expression in the pharyngeal endoder

96 perturbations demonstrates complex roles for Endothelin 1 (Edn1) signaling in the intermediate joint-

97 emonstrate rs9349379 regulates expression of endothelin 1 (EDN1), a gene located 600 kb upstream of P

98 etermine the selective affinity of EDNRA for endothelin 1 (EDN1), its major physiological ligand, and

99 ular density) and the potent vasoconstrictor endothelin 1 (EDN1); we assayed the activity of angioten

100 locus acting as a potential enhancer for the endothelin-1 (EDN1) gene.

101 d cardiovascular progenitors using WNT3A and endothelin-1 (EDN1) human recombinant proteins.

102 nduced glomerulosclerosis is associated with endothelin-1 (EDN1) release by podocytes, which mediates

103 n multiple signaling pathways, in particular Endothelin-1 (Edn1), Bone Morphogenetic Protein (BMP), a

104 s the secretion of a potent vasoconstrictor, endothelin-1 (EDN1), which continues to increase as the

105 Endothelin-1 (Edn1)-induced signaling through the endoth

106 (Ednra) expression and increased circulating endothelin-1 (Edn1).

107 NGF, miR-98, PPARgamma, fibronectin 1 (FN1), endothelin-1 (EDN1, herein referred to as ET-1), and col

108 a and recruitment of vasoconstrictors (e.g., endothelin-1; Edn1) leads to clearance of transplanted c

109 Stimulation of primary mouse podocytes with endothelin-1 elicited rapid calcium transients mediated

110 egulator of genes controlling vascular tone [endothelin-1, endothelin-1 receptor type A, and endothel

111 els mediate their spontaneous motion via the endothelin-1/endothelin receptor A pathway.

112 such as transforming growth factor beta1 and endothelin-1, enhance RBC NADPH oxidase activity and inc

113 Endothelin 1 (ET-1) and ET-2 activate two G protein-coup

114 Endothelin 1 (ET-1) evokes histamine-independent pruritu

115 des, of which 3 distinct isoforms exist, and endothelin 1 (ET-1) is the most abundant and the best-ch

116 Endothelin 1 (ET-1), mainly produced from vascular endot

117 mpaired vasodilator reactivity and increased endothelin 1 (ET-1)-mediated vasoconstriction, two abnor

118 oxygen species, which evoked the release of endothelin-1 (ET) that activated pericyte ET(A) receptor

119 teral striatal injection of vasoconstrictive endothelin-1 (ET-1) along with Abeta toxicity on CNS pat

120 newborn arteries also expresses and releases endothelin-1 (ET-1) and initiates endothelium-dependent

121 s, correlate with increased plasma levels of endothelin-1 (ET-1) and other functional markers of PH i

122 creased levels of the potent vasoconstrictor endothelin-1 (ET-1) and PHT.

123 revealed marked increases in the content of endothelin-1 (ET-1) and transforming growth factor-beta

124 Endothelin-1 (ET-1) antagonists are a possibility becaus

125 Gene profiling identified inter alia endothelin-1 (ET-1) as one of the target genes of P2Y4 i

126 Hepatic production and release of endothelin-1 (ET-1) binding to endothelin B (ETB) recept

127 Previous studies suggest that endothelin-1 (ET-1) contributes to the pathogenesis of E

128 Endothelin-1 (ET-1) dose and time-dependently up-regulat

129 ivation of endothelin-A receptor (ET(A)R) by endothelin-1 (ET-1) drives epithelial-to-mesenchymal tra

130 (NGAL), kidney injury molecule-1 (KIM-1) and endothelin-1 (ET-1) during EVKP in a series of discarded

131 Endothelial expression and the release of endothelin-1 (ET-1) in levels sufficient to initiate vas

132 Endothelin-1 (ET-1) induces matrix-associated gene expre

133 Endothelin-1 (ET-1) is a 21-amino acid vasoactive peptid

134 Endothelin-1 (ET-1) is a potent endothelial-derived vaso

135 Although endothelin-1 (ET-1) is a potent vasoconstrictor peptide

136 The vasoconstrictor peptide endothelin-1 (ET-1) is a transcriptional target of TGF-b

137 Endothelin-1 (ET-1) is a vasoactive peptide that is elev

138 Endothelin-1 (ET-1) is an indicator of endothelial injur

139 Elevated circulating endothelin-1 (ET-1) is associated with the disease.

140 Since endothelin-1 (ET-1) is implicated in blood pressure (BP)

141 termine whether vascular endothelial-derived endothelin-1 (ET-1) is important for skin Na(+) bufferin

142 ceptor mediating the vasodilatory effects of endothelin-1 (ET-1) is induced by OA-NO2 Inasmuch as ET-

143 tic brain injury or subarachnoid hemorrhage, endothelin-1 (ET-1) is induced resulting in cerebral vas

144 Endothelin-1 (ET-1) is involved in the pathogenesis of c

145 estigated whether the potent vasoconstrictor endothelin-1 (ET-1) is involved.

146 cells are a major source of TGFbeta and that endothelin-1 (ET-1) is one of the key components respons

147 Endothelin-1 (ET-1) is unique among a broad range of hyp

148 Increased endothelin-1 (ET-1) levels, disordered thiol protein sta

149 rum concentrations of the vasoactive protein endothelin-1 (ET-1) occur in the setting of systemic inf

150 The present study investigated the effect of endothelin-1 (ET-1) on cholinergic mechanisms of end-org

151 n endogenous inhibitor of NO production, and endothelin-1 (ET-1) oppose the actions of NO, suggesting

152 pig retinal arterioles under normal tone or endothelin-1 (ET-1) pre-contracted conditions and determ

153 y increasing nitric oxide and downregulating endothelin-1 (ET-1) production, has been implicated in I

154 Endothelin-1 (ET-1) promotes renal damage during cardiov

155 s including angiotensin II, aldosterone, and endothelin-1 (ET-1) that mediate the immediate benefit o

156 increased expression of the vasoconstrictor endothelin-1 (ET-1) within PASMCs.

157 edominantly responsible for producing active endothelin-1 (ET-1), a mitogenic peptide implicated in t

158 Here, we report that Endothelin-1 (ET-1), a molecular component of the postna

159 ) correlated with increased plasma levels of endothelin-1 (ET-1), a potent vasoconstrictor, in sickle

160 xpression of the endothelin axis components [endothelin-1 (ET-1), endothelin-3 (ET-3), endothelin rec

161 Vasoconstrictors, including endothelin-1 (ET-1), inhibit myocyte BK channels, leadin

162 trictions of venules from euglycemic pigs to endothelin-1 (ET-1), thromboxane analog U46619, and nore

163 ed an endogenous inhibitor of remyelination, Endothelin-1 (ET-1), which is highly expressed in reacti

164 NA (siRNA) in ventricular myocytes decreases endothelin-1 (ET-1)-dependent elevation of nuclear calci

165 ined nitric oxide (NO)-mediated dilation and endothelin-1 (ET-1)-induced constriction in retinal arte

166 dy state [Ca(2+)](i), and protection against endothelin-1 (ET-1)-induced steady state [Ca(2+)](i) inc

167 isoproterenol (ISO), phenylephrine (PE), and endothelin-1 (ET-1).

168 decreased the positive inotropic response to endothelin-1 (ET-1).

169 In EOC, the endothelin-1 (ET-1, EDN1)-endothelin A receptor (ETAR, E

170 Endothelin-1 (ET1) synthesis is understood to promote ca

171 We hypothesized that endothelin-1 (ET1), a secreted paracrine factor of ECs,

172 GFR, plasma renin concentration, and urinary endothelin-1 excretion were similar between knockout and

173 Endothelin-1 exerts its actions via activation of ET(A)

174 Mediation analysis showed that BNP and endothelin-1 explained 56% and 40%, respectively, of the

175 pain behavior, epidermal tissue damage, and endothelin-1 expression.

176 ivation and angiotensin-induced increases in endothelin-1 expression.

177 = 0.0009) expression, with no differences in endothelin-1 expression.

178 EndMT, suppression of eNOS, and induction of endothelin-1 expression.

179 e sarcomere and activation of calcineurin by endothelin-1-facilitated interaction between FHL2 and ca

180 fibroblasts were treated with 20 and 100 nM endothelin-1 for 6 and 24 hours and then collected to as

181 en a modest ( approximately 35%) decrease in endothelin-1 gene (Edn1) expression is sufficient to cau

182 dney vasculature and normalized Tgf-beta and endothelin-1 gene expression in aged MWF rats.

183 array analysis showed increased Tgf-beta and endothelin-1 gene expression with age.

184 generated low-expressing and high-expressing endothelin-1 genes (L and H) and have bred mice with fou

185 hic acid I, calcitonin gene-related peptide, endothelin-1, gentamicin, norepinephrine and vasopressin

186 ary hypertension and high endothelin-1 (high endothelin-1: >/=1.7 pg/mL; upper quartile); pulmonary h

187 ubgroup with pulmonary hypertension and high endothelin-1 (high endothelin-1: >/=1.7 pg/mL; upper qua

188 tic effect by repressing Edn1, which encodes endothelin 1 in the connecting tubule/collecting duct.

189 tions in plasma vasopressin, upregulation of endothelin-1 in cerebral resistance arterioles and activ

190 de (NO)/reactive oxygen species balance, and endothelin-1 in conduit artery endothelial dysfunction d

191 phy signaling triggered by angiotensin II or endothelin-1 in HEK293T cells as well as in neonatal and

192 A fumigatus also induced endothelin-1 in murine lungs, associated with extensive

193 Accordingly, VAMP3 co-occurred with endothelin-1 in the skins of patients with AD.

194 the expression of contractile markers and of endothelin-1 in VSMCs.

195 In human pulmonary artery endothelial cells, endothelin-1 increased aldosterone levels via peroxisome

196 In vitro, treatment with endothelin-1 increased total beta-catenin and phospho-NF

197 Furthermore, intracellular endothelin-1 increases nitric oxide via an ET(B)-depende

198 s not known whether elevated serum levels of endothelin-1 indicate future risk of kidney disease in t

199 s on d1, d7, and d28 post Abeta toxicity and endothelin-1 induced ischemia (ET1) in rats.

200 e complement anaphylatoxins C3a and C5a, and endothelin 1, induced human MCs rapidly to secrete small

201 In endothelial cells, the endothelin-1-induced Ca(2+) response is abolished upon e

202 However, endothelin-1-induced constriction was significantly enha

203 The endothelin-1-induced vasodilation in these PCOS subject,

204 Endothelin-1 induces lung fibroblast proliferation and c

205 Specifically, endothelin-1 induces sympathetic neurons expressing the

206 e CKD by enhanced ADORA2B signaling-mediated endothelin-1 induction in a hypoxia-inducible factor-alp

207 Vasoconstriction blockade with the endothelin-1 inhibitor BQ-123, or ROS scavenging after S

208 We conclude that endothelin-1 is critical for maintaining normal contract

209 Endothelin-1 is known to stimulate endothelial nitric ox

210 0.05), but not in vascular endothelial cell endothelin-1 knockout (VEET KO) mice (76.4 +/- 5.7 pg/mg

211 ular risk in black adults, we measured serum endothelin-1 level at baseline (2000-2004; n=3538).

212 Phenotyping by pulmonary hypertension and endothelin-1 level showed mortality decreasing in order

213 Log-transformed plasma endothelin-1 level.

214 heart, vascular remodeling, and raised serum endothelin 1 levels.

215 ur knowledge, the association between plasma endothelin-1 levels and pulmonary hypertension has not b

216 ied African American individuals with plasma endothelin-1 levels and tricuspid regurgitation on echoc

217 In conclusion, higher baseline serum endothelin-1 levels associated with incident CKD and all

218 en-binding activity, soluble E-selectin, and endothelin-1 levels by using ELISA and BRAHMS Kryptor te

219 consistent with the hypothesis that elevated endothelin-1 levels contribute to subepithelial thickeni

220 Participants with baseline endothelin-1 levels in higher quartiles had a greater in

221 Mean (SD) endothelin-1 levels were 1.36 (0.64) pg/mL; 217 of 3223

222 In rats with PAH, elevated endothelin-1 levels were associated with elevated aldost

223 g for potential confounders, log-transformed endothelin-1 levels were associated with increased odds

224 Log-transformed endothelin-1 levels were associated with mortality (adju

225 Mechanistically, increased endothelin-1 levels were detected in TGFbetaRII-KO endot

226 Basal and angiotensin-stimulated big endothelin-1 levels were elevated in Tg(Prkcb)apoE-/- mi

227 terminal telopeptide of collagen type I, and endothelin-1 levels were higher in diabetic patients (p

228 Endothelin-1 levels were significantly increased 20 hr a

229 Elevated plasma endothelin-1 levels, especially associated with an eleva

230 lin-1; and no pulmonary hypertension and low endothelin-1 (log-rank chi2 = 77.16; P < .01 ).

231 er quartile); pulmonary hypertension and low endothelin-1 <1.7 pg/mL; lower 3 quartiles); no pulmonar

232 wth factor-b, interleukin-1b, interleukin-6, endothelin-1, matrix metalloproteinase-9, plasminogen ac

233 tion of the endothelin-A receptor (EDNRA) by endothelin-1 may play a role in the disease because the

234 antinociceptive effect through inhibition of endothelin-1 mediated neuronal activation, revealing the

235 to histaminergic (histamine, compound 48/80, endothelin-1), not non-histaminergic (chloroquine) pruri

236 However, no direct pathogenic effect of endothelin-1 on podocytes has been shown in vivo and end

237 atory BP), arterial stiffness, nitric oxide, endothelin 1, or blood lipid profile.

238 specimens and plasma of CTEPH patients, and endothelin-1 overexpression was prevented by inhibition

239 th the concentration of the vasoconstrictor, endothelin 1 (P = 0.0005), and negatively with the conce

240 othelin-1; (d) immunohistochemistry of eNOS, endothelin-1, P-selectin, intercellular adhesion molecul

241 on in NO/reactive oxygen species balance and endothelin-1 pathway, to conduit artery endothelial dysf

242 hese results indicate that activation of the endothelin-1 pathways selectively in podocytes mediates

243 rease in eNOS expression, and an increase in endothelin-1 plasma levels, with all mice dying within 5

244 Endothelin-1 positively associated with all-cause mortal

245 Blocking endothelin-1 prevented these phenotypic changes.

246 We provide evidence that microinjected endothelin-1 produces a dose-dependent elevation in cyto

247 tes production of the potent vasoconstrictor endothelin-1, producing pulmonary hypertension.

248 ADORA2B activation that directly stimulates endothelin-1 production in a hypoxia-inducible factor-al

249 Endothelin-1 promotes mesangial cell proliferation and s

250 Endothelin-1 promotes vasculopathy in systemic sclerosis

251 l as in human disease, including the role of endothelin-1, pulmonary monocytes, and angiogenesis.

252 iewed, including nitric oxide, prostacyclin, endothelin-1, reactive oxygen species, and endothelial a

253 e with recurrent SSc-related digital ulcers) endothelin-1 receptor antagonism.

254 wn to improve Raynaud's Condition Score; the endothelin-1 receptor antagonist bosentan has now been s

255 Our data do not support the use of the dual endothelin-1 receptor antagonist, bosentan, in patients

256 Using a selective endothelin-1 receptor antagonist, we demonstrated for th

257 Treatment with endothelin-1 receptor antagonists could theoretically im

258 , whereas pretreatment of rats with the dual endothelin-1 receptor blocker, bosentan, improved cell e

259 ion was associated with increased glomerular endothelin-1 receptor type A (Ednra) expression and incr

260 nes controlling vascular tone [endothelin-1, endothelin-1 receptor type A, and endothelial nitric oxi

261 physiologically important thromboxane A2 and endothelin-1 receptors.

262 with elevated vasoconstrictor signalling via endothelin-1, reduces the local vasodilatory response to

263 esting that p66Shc expression did not affect endothelin-1 release from resident endothelial cells.

264 on vascular cells promoted interleukin-6 and endothelin-1 release.

265 activated gene networks involved in calcium, endothelin-1, renin-angiotensin, and cardiac beta-adrene

266 Acute application of endothelin-1 revealed significantly elevated production

267 ystem (leads to activation of TGF-beta), and endothelin-1 secretion by macrophages in mediating tissu

268 Of these, the vasoconstrictive factor endothelin-1 serves as an integral point of communicatio

269 e C signaling, glutamate receptor signaling, endothelin 1 signaling, and cardiac hypertrophy signalin

270 Although the autocrine/paracrine nature of endothelin-1 signaling has been extensively studied, its

271 in-1 on podocytes has been shown in vivo and endothelin-1 signaling in podocytes has not been investi

272 Our data suggest that in diabetes, endothelin-1 signaling, as occurs in endothelial activat

273 resence of an endothelin-converting enzyme 1/endothelin 1-SphK positive feedback loop.

274 Endothelin-1 stimulated the production of MMP1, MMP8, an

275 eNOS-activating region of ET(B) to decrease endothelin-1-stimulated eNOS activity.

276 ects, but not in vascular dementia, in which endothelin 1 tended to be elevated, perhaps reflecting a

277 ased pressor responses to angiotensin II and endothelin-1; these effects are prevented by treatment w

278 These pathways were activated by endothelin-1 through the ETB receptor; inhibiting recept

279 cterised by the measurement of nitric oxide, endothelin-1, tissue plasminogen activator and plasminog

280 pro-B-type natriuretic peptide, aldosterone, endothelin-1, troponin I, and C-telopeptide for type I c

281 ecipients the impact of Abs directed against endothelin-1 type A (ET(A)R) and angiotensin II type 1 r

282 cell Abs-angiotensin type 1 receptor (AT1R), endothelin-1 type A and natural polyreactive Abs-did not

283 n levels of the cannabinoid type 1 receptor, endothelin-1 type A receptor (ET(A) R), activator protei

284 anti-angiotensin II type-1 receptor and anti-endothelin-1 type A receptor autoantibodies are associat

285 tatus for angiotensin II type-1 receptor and endothelin-1 type A receptor autoantibodies pre-LT, and

286 s elicited by phenylephrine, angiotensin II, endothelin-1, U46619, and K(+)-induced membrane depolari

287 n enhances epidermal expression of TRPV4 and endothelin-1, underscoring the potential of keratinocyte

288 r analysis of the Bristol cohort showed that endothelin 1 was reduced in the white matter in Alzheime

289 PKG) activity independently of diet, whereas endothelin-1 was increased by diet and Abeta42.

290 The extracellular concentration of endothelin-1 was increased following GLO1-knockdown, whe

291 Moreover, Ca(2+) release stimulated by endothelin-1 was inhibited by Ned-19, ryanodine, or xest

292 Endothelin-1 was measured at baseline and 12 weeks.

293 amma inducible protein 10 (IP10; CXCL10) and endothelin 1 were raised and strongly correlated togethe

294 unction and the vasoconstrictive response to endothelin-1 were also observed using a liver perfusion

295 No clear associations with TNF or endothelin-1 were observed.

296 illations triggered by endogenously released endothelin-1 were recorded in smooth muscle cells of the

297 en-binding activity, soluble E-selectin, and endothelin-1) were significantly increased during HAE at

298 ce has been associated with raised levels of endothelin-1, which are common both before and after Fon

299 f humoral factors such as angiotensin II and endothelin-1, which in turn promote cardiac hypertrophy

300 es was increased expression and secretion of endothelin-1, which is also a known pruritogen.